Psilocybin Research: The Complete Timeline of Clinical Trials

## The Short Answer Psilocybin research has a 70-year history interrupted by a 30-year prohibition. The modern research era began in 2000 when Johns Hopkins received FDA approval for the first human psilocybin study in decades. Since then, over 100 clinical trials have been completed or are underway. The FDA granted Breakthrough Therapy designation for psilocybin in treatment-resistant depression in 2018. An FDA advisory committee reviewed MDMA-assisted therapy in 2024 — the decision will set precedent for psilocybin approval. ## The Research Timeline **1950s–1960s:** Albert Hofmann synthesizes psilocybin (1958). Hundreds of studies conducted on therapeutic applications. Timothy Leary\'s Harvard Psilocybin Project (1960–1962). **1970:** Controlled Substances Act classifies psilocybin as Schedule I. Research effectively halted for 30 years. **2000:** Johns Hopkins receives FDA approval for first modern human psilocybin study. **2006:** Griffiths et al. publish landmark *Psychopharmacology* study showing psilocybin produces mystical experiences with lasting positive effects in healthy volunteers. **2014:** Johnson et al. (Johns Hopkins) publish smoking cessation pilot: 80% abstinence at 6 months. **2016:** Simultaneous Johns Hopkins and NYU trials show psilocybin reduces end-of-life anxiety in cancer patients. **2018:** FDA grants Breakthrough Therapy designation for psilocybin in treatment-resistant depression. **2020:** Oregon voters pass Measure 109, legalizing supervised psilocybin therapy. **2021:** COMPASS Pathways Phase 2b trial (233 patients) shows significant depression reduction. Davis et al. (Johns Hopkins) publish major depression RCT: 71% response, 54% remission. **2022:** MAPS MDMA trial published in *Nature Medicine*. Psilocybin trials for alcohol use disorder published in *JAMA Psychiatry*. **2024:** FDA advisory committee reviews MDMA-assisted therapy — decision will set regulatory precedent for psilocybin. [See the protocol →](/research-checkout) *This article is for informational purposes only and does not constitute medical advice.*

The journey of psilocybin from ancient spiritual practices to modern medicine is a testament to scientific curiosity and evolving societal perspectives. While its therapeutic potential was recognized decades ago, a period of prohibition significantly hampered research. Today, we stand at the precipice of a new era, with groundbreaking studies and regulatory shifts paving the way for psilocybin-assisted therapies. This comprehensive timeline delves into the pivotal moments that have shaped psilocybin research, from its initial discovery to the cutting-edge clinical trials and regulatory milestones of the present day.

The Early Years: Discovery and Initial Exploration (1950s-1960s)

The modern history of psilocybin research began in 1958 when Swiss chemist Albert Hofmann, already known for synthesizing LSD, successfully isolated psilocybin and psilocin from the Psilocybe mexicana mushroom [Hofmann, 1958]. This breakthrough allowed for standardized dosing and controlled scientific investigation, moving beyond anecdotal reports of traditional use. The 1950s and 1960s saw a flurry of research activity, with hundreds of studies exploring psilocybin\'s potential in psychotherapy, addiction treatment, and understanding consciousness. Prominent figures like Timothy Leary at Harvard University conducted experiments, albeit controversially, that highlighted the profound subjective experiences induced by psilocybin [Leary et al., 1964]. Early findings suggested promise for treating conditions such as anxiety, depression, and alcoholism, laying a foundational, albeit often overlooked, groundwork for future research.

The Dark Ages: Prohibition and Research Hiatus (1970s-1990s)

The burgeoning psychedelic research landscape came to an abrupt halt with the passage of the Controlled Substances Act in 1970 in the United States, which classified psilocybin as a Schedule I substance. This classification, designating it as having a high potential for abuse and no accepted medical use, effectively shut down scientific inquiry for over three decades. Similar legislative actions in other countries mirrored this global prohibition, leading to a significant loss of momentum and a generation of researchers unable to explore these compounds. Despite the scientific community\'s growing understanding of neurobiology and mental health, psilocybin remained largely inaccessible for legitimate study, pushing its use into underground contexts.

The Renaissance: Resurgence of Modern Research (2000s-Present)

The dawn of the 21st century marked a turning point. In 2000, Johns Hopkins University received the first FDA approval in decades to conduct human studies with psilocybin, signaling the beginning of a new, more rigorous era of research. This pivotal moment opened the floodgates for renewed scientific interest, focusing on controlled clinical trials to evaluate psilocybin\'s safety and efficacy for various mental health conditions.

Key Milestones and Landmark Studies:

• 2006: Mystical Experiences and Well-being — A landmark study by Griffiths et al. at Johns Hopkins, published in *Psychopharmacology*, demonstrated that psilocybin could occasion mystical-type experiences that had lasting positive effects on attitudes, mood, and behavior in healthy volunteers [Griffiths et al., 2006]. This study was crucial in re-establishing psilocybin\'s potential for therapeutic benefit within a scientific framework.
• 2014: Smoking Cessation — Johnson et al. (Johns Hopkins) published a pilot study showing remarkable efficacy of psilocybin-assisted therapy for smoking cessation, with an 80% abstinence rate at 6 months, significantly higher than traditional methods [Johnson et al., 2014].
• 2016: End-of-Life Anxiety — Simultaneous studies from Johns Hopkins and New York University demonstrated that a single dose of psilocybin significantly reduced anxiety and depression in cancer patients with life-threatening diagnoses, with effects lasting for months [Griffiths et al., 2016; Ross et al., 2016].
• 2018: FDA Breakthrough Therapy Designation — The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression (TRD), acknowledging its potential to offer substantial improvement over available therapies. This designation expedites the development and review process for promising new drugs [FDA, 2018].
• 2020: Oregon\'s Measure 109 — Oregon became the first U.S. state to legalize supervised psilocybin therapy for adults, creating a regulated framework for its therapeutic use outside of clinical trials [Oregon Health Authority, 2020].
• 2021: Major Depression Trials — COMPASS Pathways announced positive results from its Phase 2b trial (COMP001) involving 233 patients with TRD, showing significant reductions in depression scores [COMPASS Pathways, 2021]. Concurrently, Davis et al. (Johns Hopkins) published an RCT in *JAMA Psychiatry* demonstrating rapid and sustained antidepressant effects of psilocybin in patients with major depressive disorder (MDD), with 71% response and 54% remission rates [Davis et al., 2021].
• 2022: Alcohol Use Disorder — Research published in *JAMA Psychiatry* showed that psilocybin-assisted psychotherapy significantly reduced heavy drinking days in individuals with alcohol use disorder [Bogenschutz et al., 2022].

The Current Landscape: Clinical Trials and Regulatory Progress (2024-2026)

The pace of psilocybin research has accelerated dramatically in recent years, with numerous clinical trials underway globally. The focus has expanded beyond depression and anxiety to include conditions like PTSD, anorexia nervosa, and obsessive-compulsive disorder. The regulatory environment is also rapidly evolving, with the FDA playing a crucial role in guiding the development of psychedelic medicines.

FDA Guidance and Breakthrough Therapy Designations:

In June 2023, the FDA issued its first draft guidance on clinical trials with psychedelic drugs, providing researchers with considerations for study design, data collection, and subject safety [FDA, 2023]. This guidance underscores the FDA\'s commitment to facilitating the development of these compounds while ensuring rigorous scientific standards. Beyond the initial Breakthrough Therapy designation in 2018, the FDA has continued to grant this status to other psilocybin programs, including Usona Institute\'s psilocybin for MDD in 2019 [Medscape, 2019] and more recently, CYB003, a deuterated psilocybin analog by Cybin Inc., for MDD in 2024 [UTHealth Houston, 2024]. These designations highlight the significant unmet medical need and the promising preliminary evidence for psilocybin\'s therapeutic potential.

COMPASS Pathways and the Race to Approval:

COMPASS Pathways remains at the forefront of psilocybin research, particularly with its COMP360 psilocybin therapy for treatment-resistant depression. The company has successfully completed two consecutive positive Phase 3 trials (COMP005 in June 2025 and COMP006 in February 2026), demonstrating high statistical significance in hitting primary endpoints [Psychedelic Beacon, 2026]. These trials involved over 1,000 participants, with results showing significant reductions in depression scores and sustained effects. Safety profiles have been consistent, with most adverse events being transient and mild. The company has initiated a rolling New Drug Application (NDA) submission with the FDA, with a potential approval decision anticipated by late 2026 or early 2027, which would mark a historic milestone as the first classic psychedelic approved by the FDA [Psychedelic Beacon, 2026].

The recent Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," signed by President Trump in April 2026, further emphasizes the federal government\'s commitment to expediting the review of psychedelic drugs with Breakthrough Therapy designation. This executive order, coupled with the FDA\'s issuance of Commissioner\'s National Priority Vouchers (CNPVs) to programs like COMPASS Pathways and Usona Institute, aims to significantly compress the NDA review timeline, potentially leading to FDA approval as early as Q4 2026 or Q1 2027 [Psychedelic Beacon, 2026]. This rapid acceleration underscores the urgency and perceived potential of psilocybin as a transformative treatment for severe mental health conditions.

The Broader Psilocybin and Psychedelic Clinical Pipeline:

While COMPASS Pathways leads the race, the broader psychedelic pipeline is robust and diverse. Usona Institute, a non-profit research organization, holds a second FDA Breakthrough Therapy Designation for psilocybin in major depressive disorder (MDD), a broader indication than TRD. Their Phase 3 trial (uAspire, NCT06308653) launched in March 2024, aiming to enroll approximately 240 adults [Psychedelic Beacon, 2026]. Other companies are also advancing novel psychedelic compounds, including methylone for PTSD (Transcend Therapeutics), mebufotenin (BPL-003, GH001), deuterated psilocin (Helus HLP003), and luvesilocin (Reunion RE104), all of which are potentially in scope for accelerated review under the new executive order [Psychedelic Beacon, 2026]. The FDA\'s recent clearance of an IND for DemeRx NB\'s noribogaine hydrochloride in alcohol use disorder also marks the first U.S. ibogaine-derivative clinical trial approval, further diversifying the therapeutic landscape.

Key Psilocybin Clinical Trial Milestones

Year	Event/Study	Key Finding/Significance	Citation
1958	Albert Hofmann isolates psilocybin	Enables standardized research into psilocybin.	[Hofmann, 1958]
2000	Johns Hopkins receives FDA approval for human psilocybin study	Marks the beginning of modern psilocybin research era.
2006	Griffiths et al. study on mystical experiences	Psilocybin can occasion mystical experiences with lasting positive effects.	[Griffiths et al., 2006]
2014	Johnson et al. smoking cessation pilot	80% abstinence rate at 6 months with psilocybin-assisted therapy.	[Johnson et al., 2014]
2016	Studies on end-of-life anxiety in cancer patients	Psilocybin significantly reduces anxiety and depression for months.	[Griffiths et al., 2016; Ross et al., 2016]
2018	FDA grants Breakthrough Therapy designation for TRD	Expedites development and review for treatment-resistant depression.	[FDA, 2018]
2020	Oregon voters pass Measure 109	Legalizes supervised psilocybin therapy in Oregon.	[Oregon Health Authority, 2020]
2021	COMPASS Pathways Phase 2b trial & Davis et al. MDD study	Significant depression reduction; 71% response, 54% remission in MDD.	[COMPASS Pathways, 2021; Davis et al., 2021]
2022	Psilocybin trials for alcohol use disorder	Significant reduction in heavy drinking days.	[Bogenschutz et al., 2022]
2023	FDA issues first draft guidance on psychedelic clinical trials	Provides researchers with considerations for study design and safety.	[FDA, 2023]
2024	CYB003 receives FDA Breakthrough Therapy designation	Further highlights potential for psilocybin analogs in MDD.	[UTHealth Houston, 2024]
2026	COMPASS Pathways completes Phase 3 trials (COMP005 & COMP006)	Positive results for COMP360 in treatment-resistant depression.	[Psychedelic Beacon, 2026]
2026	Executive Order 14401 & CNPVs issued	Accelerates FDA review for psychedelic drugs with BTD.	[Psychedelic Beacon, 2026]

Regulatory Challenges and Future Outlook

Despite the promising clinical data and accelerated regulatory pathways, significant challenges remain. Psilocybin, along with other classic psychedelics, remains classified as a Schedule I controlled substance. While the executive order contemplates parallel DEA rescheduling review, practical acceleration has yet to fully materialize, and any rescheduling would likely be product-specific rather than substance-wide [Psychedelic Beacon, 2026]. This means that even after FDA approval, the specific formulation (e.g., COMP360) would need to undergo a separate DEA review process before it can be legally prescribed and dispensed. Furthermore, issues of patient access, insurance coverage, and the integration of psilocybin-assisted therapy into existing healthcare systems are complex and will require careful navigation. The role of psychotherapy in conjunction with psilocybin administration is also a critical component, and ensuring adequate training and availability of qualified therapists will be essential for widespread implementation.

The evolving legal landscape at the state level, with initiatives like Oregon\'s Measure 109 and Colorado\'s Natural Medicine Health Act, demonstrates a growing public and legislative interest in expanding access to psychedelic therapies. These state-level programs, while distinct from federal FDA approval, contribute to a broader ecosystem of research and therapeutic exploration. As clinical trials continue to yield positive results and regulatory bodies adapt to this new paradigm, the future of psilocybin in mental healthcare appears increasingly bright. The potential for these compounds to address intractable conditions like treatment-resistant depression, PTSD, and addiction offers a beacon of hope for millions worldwide. Shrooomz is committed to staying informed on these developments and providing access to high-quality functional mushroom products that support overall well-being.

Understanding Psilocybin\'s Mechanism of Action

Psilocybin\'s therapeutic effects are believed to stem from its interaction with serotonin 5-HT2A receptors in the brain. This interaction leads to a cascade of neurobiological changes, including increased neuroplasticity, enhanced neural connectivity, and a temporary disruption of rigid thought patterns associated with mental health disorders. Studies using functional magnetic resonance imaging (fMRI) have shown that psilocybin can reduce activity in the default mode network (DMN), a brain network implicated in self-referential thought and rumination, which is often overactive in depression and anxiety [Carhart-Harris et al., 2012]. By transiently reducing DMN activity, psilocybin may allow for a more flexible and adaptive cognitive state, facilitating new perspectives and emotional processing during therapy. This enhanced neuroplasticity is a key factor in its long-lasting therapeutic effects, potentially \'rewiring\' the brain to break free from entrenched negative thought cycles psilocybin-neuroplasticity-how-mushrooms-rewire-brain.

The Role of Psilocybin in Neuroplasticity

Neuroplasticity, the brain\'s ability to reorganize itself by forming new neural connections throughout life, is a critical component of learning, memory, and recovery from brain injury. Emerging research suggests that psilocybin significantly enhances neuroplasticity, a mechanism that may underlie its profound and enduring therapeutic effects. Studies have shown that psilocybin can promote the growth of new dendrites and dendritic spines in cortical neurons, essentially increasing the number of connections between brain cells [Ly et al., 2018]. This \'rewiring\' capability is particularly relevant for conditions like depression and PTSD, where neural circuits can become rigid and maladaptive. By fostering a more flexible and interconnected brain state, psilocybin-assisted therapy can help individuals break free from entrenched negative thought patterns and behaviors, facilitating the integration of new insights and coping mechanisms psilocybin-neuroplasticity-how-mushrooms-rewire-brain. This makes psilocybin a powerful tool not just for symptom reduction, but for promoting fundamental changes in brain function that support long-term mental health.

Psilocybin and Depression Treatment: A Deeper Dive

The potential of psilocybin to treat depression, particularly treatment-resistant depression (TRD) and major depressive disorder (MDD), has been a primary focus of modern research. Traditional antidepressants often come with significant side effects and may not be effective for a substantial portion of patients. Psilocybin-assisted therapy offers a novel approach, often requiring only one or two administrations in a therapeutic setting to produce rapid and sustained antidepressant effects. Clinical trials have consistently demonstrated significant reductions in depression severity, with many patients achieving remission psilocybin-clinical-trials-depression-results. The therapeutic process typically involves preparation sessions, a guided psilocybin experience, and integration sessions, where patients process their insights and experiences. This comprehensive approach, combined with the neuroplastic effects of psilocybin, appears to facilitate deep psychological shifts that can lead to lasting improvements in mood and well-being. For individuals struggling with chronic depression, psilocybin offers a promising alternative to conventional treatments, potentially providing relief where other therapies have failed microdosing-mushrooms-depression.

Microdosing Psilocybin: A Growing Area of Interest

Beyond clinical settings, there is growing public interest in microdosing psilocybin – the practice of consuming sub-perceptual doses of psychedelics. Proponents suggest that microdosing can enhance creativity, improve mood, increase focus, and reduce symptoms of anxiety and depression without inducing a full psychedelic experience. While anecdotal reports are abundant, scientific research on microdosing is still in its early stages. Preliminary studies and observational data suggest potential benefits, but more rigorous, placebo-controlled trials are needed to fully understand its efficacy, optimal dosing, and long-term effects how-to-start-microdosing-psilocybin-science-based-protocol. The appeal of microdosing lies in its potential to integrate the benefits of psilocybin into daily life, offering a subtle yet impactful way to support mental and emotional well-being. As research progresses, a clearer picture of microdosing\'s therapeutic potential and safety profile will emerge.

References

• [Hofmann, 1958] Hofmann, A. (1958). Psilocybin, ein psychotroper Wirkstoff aus Psilocybe mexicana Heim. *Experientia*, 14(11), 397-399.
• [Leary et al., 1964] Leary, T., Litwin, G. H., & Metzner, R. (1964). Reactions to psilocybin administered in a supportive environment. *The Journal of Nervous and Mental Disease*, 139(1), 77-87.
• [Griffiths et al., 2006] Griffiths, R. R., Richards, W. A., McCann, U. D., & Jesse, G. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, 187(3), 268-283.
• [Johnson et al., 2014] Johnson, M. W., Garcia-Romeu, M., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology*, 28(11), 983-992.
• [Griffiths et al., 2016] Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., ... & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized, double-blind, placebo-controlled trial. *Journal of Psychopharmacology*, 30(12), 1181-1197.
• [Ross et al., 2016] Ross, S., Bossis, O., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., ... & Bogenschutz, M. (2016). Rapid and sustained symptom reduction following psilocybin-assisted psychotherapy for anxiety and depression in patients with life-threatening cancer: A randomized, controlled trial. *Journal of Psychopharmacology*, 30(12), 1165-1180.
• [FDA, 2018] U.S. Food and Drug Administration. (2018). *FDA grants Breakthrough Therapy designation for psilocybin for treatment-resistant depression*. [Press Release].
• [Oregon Health Authority, 2020] Oregon Health Authority. (2020). *Oregon Psilocybin Services*.
• [COMPASS Pathways, 2021] COMPASS Pathways. (2021). *COMPASS Pathways announces positive topline results from its Phase 2b trial of psilocybin therapy for treatment-resistant depression*. [Press Release].
• [Davis et al., 2021] Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2021). Effects of psilocybin-assisted psychotherapy on depression and anxiety in patients with major depressive disorder: A randomized clinical trial. *JAMA Psychiatry*, 78(10), 1087-1097.
• [Bogenschutz et al., 2022] Bogenschutz, M. P., Ross, S., Pomara, N., Hood, S. D., Johnson, M. W., Garcia-Romeu, M., ... & Forcehimes, A. A. (2022). Percentage of heavy drinking days after psilocybin-assisted psychotherapy vs placebo with psychotherapy for patients with alcohol use disorder: A randomized clinical trial. *JAMA Psychiatry*, 79(10), 954-964.
• [FDA, 2023] U.S. Food and Drug Administration. (2023). *FDA issues first draft guidance on clinical trials with psychedelic drugs*. [Press Release].
• [Medscape, 2019] Medscape. (2019). *FDA Grants Psilocybin Second Breakthrough Therapy Designation*.
• [UTHealth Houston, 2024] UTHealth Houston. (2024). *FDA Grants Breakthrough Therapy Designation to CYB003, a Deuterated Psilocybin Analog Being Investigated as an Adjunctive Treatment for Major Depressive Disorder (MDD)*. [Press Release].
• [Psychedelic Beacon, 2026] Psychedelic Beacon. (2026). *Psilocybin FDA Approval Status (Updated May 2026) — Tracker & Timeline*. Retrieved from https://psychedelicbeacon.com/blog/psilocybin-fda-approval-tracker
• [Carhart-Harris et al., 2012] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Evans, L., Thase, A. F., ... & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences*, 109(6), 2138-2143.
• [Ly et al., 2018] Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., ... & Olson, D. E. (2018). Psychedelics promote structural and functional neuroplasticity. *Cell Reports*, 23(11), 3170-3182.

Frequently Asked Questions

Q: What is psilocybin and how does it work?

A: Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. When ingested, it is converted in the body to psilocin, which interacts with serotonin 5-HT2A receptors in the brain. This interaction is believed to lead to altered perceptions, mood changes, and profound introspective experiences. Therapeutically, it is thought to increase neuroplasticity and reduce activity in the default mode network, which can help break negative thought patterns associated with depression and anxiety.

Q: Is psilocybin legal?

A: Federally, psilocybin remains a Schedule I controlled substance in the United States, meaning it has a high potential for abuse and no accepted medical use. However, there is a growing movement towards decriminalization and legalization at the state level, such as Oregon and Colorado, which have established regulated frameworks for supervised psilocybin therapy. Clinical trials are also conducted under specific regulatory approvals. The legal status is complex and evolving, so it is important to stay informed about local regulations.

Q: What conditions can psilocybin treat?

A: Research suggests psilocybin has therapeutic potential for a range of mental health conditions, including treatment-resistant depression (TRD), major depressive disorder (MDD), anxiety, post-traumatic stress disorder (PTSD), and alcohol use disorder. Studies have also explored its use in reducing end-of-life distress in cancer patients. While results are promising, it is still considered an investigational treatment, and further research is ongoing.

Q: What is the difference between psilocybin therapy and microdosing?

A: Psilocybin therapy typically involves one or a few high-dose administrations in a controlled, therapeutic setting, often accompanied by psychotherapy. The goal is to induce a profound psychedelic experience that can lead to significant psychological insights and lasting therapeutic effects. Microdosing, on the other hand, involves consuming sub-perceptual doses of psilocybin, usually on a regular schedule, without aiming for a full psychedelic experience. Proponents suggest microdosing can enhance mood, creativity, and focus, but scientific research on its efficacy and long-term effects is still in early stages.

Q: When might psilocybin be FDA approved?

A: With ongoing Phase 3 clinical trials and recent regulatory accelerations, such as the FDA\'s Breakthrough Therapy designations and the issuance of Commissioner\'s National Priority Vouchers, a psilocybin-assisted therapy could potentially receive FDA approval as early as late 2026 or early 2027. This would mark a historic milestone, making it the first classic psychedelic approved for medical use in the U.S. However, regulatory timelines can be subject to change, and subsequent DEA rescheduling would also be required before widespread availability.